Curis announced the opening of eleven new clinical trial sites for its emavusertib combination regimen in the TakeAim CLL trial. The site expansion speeds up enrollment and data collection, potentially accelerating the regulatory pathway for a promising targeted therapy in a high‑need oncology market. Curis (sponsor), investigational sites across the United States, patients with relapsed/refractory chronic lymphocytic leukemia, and the TakeAim trial collaborators. Expect increased enrollment rates, interim efficacy readouts later in 2026, and subsequent discussions with the FDA regarding possible accelerated approval pathways. Curis has announced the activation of eleven clinical trial sites for its emavusertib combination regimen within the TakeAim CLL study, signalling a push to accelerate patient enrollment. The move underscores confidence in the drug’s early‑stage activity and aims to generate sufficient data for a potential regulatory readout in the near term. While the expansion is operationally straightforward, success will hinge on achieving efficacy endpoints that differentiate the therapy in a crowded CLL landscape.
INTELLIGENCE
Social Pulse
AI estimate · not scraped